Down-regulation of vimentin by triorganotin
isothiocyanates-nuclear retinoid X receptor agonists: A
proteomic approach

J 2020

Down-regulation of vimentin by triorganotin isothiocyanates-nuclear retinoid X receptor agonists: A proteomic approach

STROUHALOVA, D., D. MACEJOVA, B. MOSNA, Pavel BOBÁĽ, Jan OTEVŘEL et. al.

Basic information

Original name

Down-regulation of vimentin by triorganotin isothiocyanates-nuclear retinoid X receptor agonists: A proteomic approach

Authors

STROUHALOVA, D., D. MACEJOVA, B. MOSNA, Pavel BOBÁĽ (703 Slovakia, belonging to the institution), Jan OTEVŘEL (203 Czech Republic, belonging to the institution), M. LASTOVICKOVA, J. BRTKO and J. BOBALOVA

Edition

Toxicology Letters, CLARE, Elsevier, 2020, 0378-4274

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.372

RIV identification code

RIV/00216224:14160/20:00118220

Organization unit

Faculty of Pharmacy

DOI

http://dx.doi.org/10.1016/j.toxlet.2019.10.004

UT WoS

000496792900003

Keywords in English

Triorganotin isothiocyanates; Breast cancer; Proteomic; iTRAQ; Vimentin

Abstract

V originále

An attempt has been made to delineate the role of natural and synthetic retinoid receptor ligands on vimentin expression in the human triple-negative breast cancer cells. The effects of currently synthesized triorganotin derivatives of the general formula R3SnX (R is butyl or phenyl, X is isothiocyanate), which are considered RXR ligands, were investigated in the human MDA-MB-231 breast cancer cell line. Studies were evaluated in the presence and absence of all-trans retinoic acid (ATRA), a natural RAR ligand. Vimentin represents the major protein associated with epithelial-mesenchymal transition (EMT), an essential process when the primary tumour transforms into a malignant one. mRNA and proteomic data obtained in this study, based on the PDQuest software protein evaluation and further quantification of proteins by iTRAQ analysis, suggest that vimentin was significantly reduced in the combination of RAR ligand and RXR ligand treatment. Both tested triorganotin compounds showed similarly reduced expression of vimentin, but tributyltin isothiocyanate (TBT-ITC) proved to be more effective than triphenyltin isothiocyanate (TPT-ITC). Furthermore, the effect of natural (9cRA) and synthetic RXR ligands, both chloride and isothiocyanate derivatives, on vimentin expression was compared.

Citovat

STROUHALOVA, D., D. MACEJOVA, B. MOSNA, Pavel BOBÁĽ, Jan OTEVŘEL, M. LASTOVICKOVA, J. BRTKO and J. BOBALOVA. Down-regulation of vimentin by triorganotin isothiocyanates-nuclear retinoid X receptor agonists: A proteomic approach. Toxicology Letters. CLARE: Elsevier, 2020, vol. 318, No 318, p. 22-29. ISSN 0378-4274. Available from: https://dx.doi.org/10.1016/j.toxlet.2019.10.004.

@article{1744776,
   author = {Strouhalova, D. and Macejova, D. and Mosna, B. and Bobáľ, Pavel and Otevřel, Jan and Lastovickova, M. and Brtko, J. and Bobalova, J.},
   article_location = {CLARE},
   article_number = {318},
   doi = {http://dx.doi.org/10.1016/j.toxlet.2019.10.004},
   keywords = {Triorganotin isothiocyanates; Breast cancer; Proteomic; iTRAQ; Vimentin},
   language = {eng},
   issn = {0378-4274},
   journal = {Toxicology Letters},
   title = {Down-regulation of vimentin by triorganotin isothiocyanates-nuclear retinoid X receptor agonists: A proteomic approach},
   url = {https://www.sciencedirect.com/science/article/pii/S0378427419303236},
   volume = {318},
   year = {2020}
}

TY  - JOUR
ID  - 1744776
AU  - Strouhalova, D. - Macejova, D. - Mosna, B. - Bobáľ, Pavel - Otevřel, Jan - Lastovickova, M. - Brtko, J. - Bobalova, J.
PY  - 2020
TI  - Down-regulation of vimentin by triorganotin isothiocyanates-nuclear retinoid X receptor agonists: A proteomic approach
JF  - Toxicology Letters
VL  - 318
IS  - 318
SP  - 22-29
EP  - 22-29
PB  - Elsevier
SN  - 03784274
KW  - Triorganotin isothiocyanates
KW  - Breast cancer
KW  - Proteomic
KW  - iTRAQ
KW  - Vimentin
UR  - https://www.sciencedirect.com/science/article/pii/S0378427419303236
N2  - An attempt has been made to delineate the role of natural and synthetic retinoid receptor ligands on vimentin expression in the human triple-negative breast cancer cells. The effects of currently synthesized triorganotin derivatives of the general formula R3SnX (R is butyl or phenyl, X is isothiocyanate), which are considered RXR ligands, were investigated in the human MDA-MB-231 breast cancer cell line. Studies were evaluated in the presence and absence of all-trans retinoic acid (ATRA), a natural RAR ligand. Vimentin represents the major protein associated with epithelial-mesenchymal transition (EMT), an essential process when the primary tumour transforms into a malignant one. mRNA and proteomic data obtained in this study, based on the PDQuest software protein evaluation and further quantification of proteins by iTRAQ analysis, suggest that vimentin was significantly reduced in the combination of RAR ligand and RXR ligand treatment. Both tested triorganotin compounds showed similarly reduced expression of vimentin, but tributyltin isothiocyanate (TBT-ITC) proved to be more effective than triphenyltin isothiocyanate (TPT-ITC). Furthermore, the effect of natural (9cRA) and synthetic RXR ligands, both chloride and isothiocyanate derivatives, on vimentin expression was compared.
ER  -

STROUHALOVA, D., D. MACEJOVA, B. MOSNA, Pavel BOBÁĽ, Jan OTEVŘEL, M. LASTOVICKOVA, J. BRTKO and J. BOBALOVA. Down-regulation of vimentin by triorganotin isothiocyanates-nuclear retinoid X receptor agonists: A proteomic approach. \textit{Toxicology Letters}. CLARE: Elsevier, 2020, vol.~318, No~318, p.~22-29. ISSN~0378-4274. Available from: https://dx.doi.org/10.1016/j.toxlet.2019.10.004.

Detailed Information on Publication Record